Circulating cell-free DNA (ccfDNA) has been shown to be associated with the clinical characteristics and prognosis of cancer patients. Our objective was to assess whether the concentration and integrity index of ccfDNA in plasma may be useful for diagnosing and monitoring the progression of patients with lymphoma. We included plasma samples from 174 lymphoma patients and 80 healthy individuals. The total concentration of ccfDNA was determined using a fluorometry method, and the DNA integrity index (DII), which is the ratio of longer to shorter DNA fragments, for the APP gene was detected using real-time quantitative PCR. The median levels of the ccfDNA concentration and the DII in patients with lymphoma were significantly higher than those in controls (both P < 0.0001). Increases in the ccfDNA concentration and the DII were associated with advanced stage disease, elevated lactate dehydrogenase levels, and a higher prognosis score. In patients with diffuse large B cell lymphoma (DLBCL), high levels of ccfDNA (both concentration and the DII) showed an inferior 2-year progression-free survival (PFS) (P = 0.001; P < 0.0001, respectively). Our study provides quantitative and qualitative evidence in favor of using ccfDNA analysis in lymphoma patients for diagnostic and prognostic assessments.
Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguin chez l'homme. CR Acad Sci Paris 142:241–243
Lo YM, Rainer TH, Chan LY et al (2000) Plasma DNA as a prognostic marker in trauma patients. Clin Chem 46:319–323 PubMed
Leon SA, Shapiro B, Sklaroff DM et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646–650 PubMed
Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665 PubMed
Shipp MA, Harrington DP, Anderson JR et al (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994 CrossRef
Hyun KA, Kim J, Gwak H et al (2015) Isolation and enrichment of circulating biomarkers for cancer screening, detection, and diagnostics. Analyst 141:382–392 CrossRef
GarcRev Can DC, Ruiz-Piqueras R, Garcerasuer D (2004) Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol 19:575–583
Melani C, Roschewski M. (2016) Molecular monitoring of cell-free circulating tumor DNA in non-Hodgkin lymphoma. Oncol (Williston Park) 30.
- Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II